NEW YORK (GenomeWeb News) – French biomarker firm Skuldtech today announced it has been awarded €1 million ($1.3 million) in funding to support work on developing diagnostic tests for an Alzheimer's drug in development.

The funding is from Bpifrance, a French public financing structure, and is part of a project on Alzheimer's that has received €8.6 million in total funding. The program, Skuldtech said, is anticipated to last four years with the first results expected in 2018.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.